1. Home
  2. BFS vs MLYS Comparison

BFS vs MLYS Comparison

Compare BFS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BFS
  • MLYS
  • Stock Information
  • Founded
  • BFS 1993
  • MLYS 2019
  • Country
  • BFS United States
  • MLYS United States
  • Employees
  • BFS N/A
  • MLYS N/A
  • Industry
  • BFS Real Estate Investment Trusts
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BFS Real Estate
  • MLYS Health Care
  • Exchange
  • BFS Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • BFS 873.4M
  • MLYS 893.0M
  • IPO Year
  • BFS 1993
  • MLYS 2023
  • Fundamental
  • Price
  • BFS $34.65
  • MLYS $12.24
  • Analyst Decision
  • BFS Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • BFS 1
  • MLYS 3
  • Target Price
  • BFS $45.50
  • MLYS $33.00
  • AVG Volume (30 Days)
  • BFS 51.0K
  • MLYS 2.3M
  • Earning Date
  • BFS 05-01-2025
  • MLYS 05-08-2025
  • Dividend Yield
  • BFS 6.67%
  • MLYS N/A
  • EPS Growth
  • BFS N/A
  • MLYS N/A
  • EPS
  • BFS 1.63
  • MLYS N/A
  • Revenue
  • BFS $268,847,000.00
  • MLYS N/A
  • Revenue This Year
  • BFS $7.78
  • MLYS N/A
  • Revenue Next Year
  • BFS $6.78
  • MLYS N/A
  • P/E Ratio
  • BFS $21.70
  • MLYS N/A
  • Revenue Growth
  • BFS 4.53
  • MLYS N/A
  • 52 Week Low
  • BFS $34.98
  • MLYS $8.24
  • 52 Week High
  • BFS $42.39
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • BFS 43.17
  • MLYS 46.14
  • Support Level
  • BFS $35.65
  • MLYS $13.00
  • Resistance Level
  • BFS $36.51
  • MLYS $17.17
  • Average True Range (ATR)
  • BFS 0.56
  • MLYS 1.44
  • MACD
  • BFS 0.03
  • MLYS -0.46
  • Stochastic Oscillator
  • BFS 35.07
  • MLYS 2.19

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates, and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: